MESO (Mesoblast) Common Stock : $1,320.21 Mil (As of Dec. 2024)

View and export this data going back to 2010. Start your Free Trial

What is Mesoblast Common Stock?

Mesoblast's quarterly common stock declined from Jun. 2024 ($1,310.81 Mil) to Sep. 2024 ($0.00 Mil) but then increased from Sep. 2024 ($0.00 Mil) to Dec. 2024 ($1,320.21 Mil).

Mesoblast's annual common stock increased from Jun. 2022 ($1,165.31 Mil) to Jun. 2023 ($1,249.12 Mil) and increased from Jun. 2023 ($1,249.12 Mil) to Jun. 2024 ($1,310.81 Mil).

Mesoblast Common Stock Historical Data

The historical data trend for Mesoblast's Common Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Mesoblast Common Stock Chart

Mesoblast Annual Data

Trend

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Jun24

Common Stock

Get a 7-Day Free Trial

1,051.45

1,163.15

1,165.31

1,249.12

1,310.81

Mesoblast Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Common Stock	Get a 7-Day Free Trial															1,286.23	-	1,310.81	-	1,320.21

Mesoblast Common Stock Calculation

Common stock is listed on the Balance Sheet at the par value of the total shares outstanding of a company.

The par value of common stocks is meaningless. It is usually set at an absurdly low number.

Mesoblast Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Mesoblast Ltd (NAS:MESO) » Definitions » Common Stock

Comparable Companies

Traded in Other Exchanges

MEOBF:USA LWB:Germany LWB1:Germany MSB:Australia

Address

55 Collins Street, Level 38, Melbourne, VIC, AUS, 3000

Website

https://www.mesoblast.com

Mesoblast Ltd is a biotechnology company. It uses its proprietary technology platform to develop and commercialize allogeneic cellular medicines to treat complex diseases resistant to conventional standards of care and where inflammation plays a central role. The company's product candidates include; Ryoncil (remestemcel-L) for the treatment of steroid refractory acute graft versus host disease as well as for the treatment of moderate to severe acute respiratory distress syndrome; Revascor (rexlemestrocel-L) for the treatment of chronic heart failure; and Rexlemestrocel-L for chronic low back pain. The company is managed as one operating segment, being the development of cell technology platform for commercialization.